

## Henry Schein Acquires W. & J. Dunlop Ltd., A Leading U.K. Animal Health Products Supplier

August 29, 2007

MELVILLE, N.Y.--(BUSINESS WIRE)--Aug. 29, 2007--Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, today announced that it has acquired W. & J. Dunlop Ltd. ("Dunlops"), a leading supplier of animal health products and services to veterinary clinics in the U.K. With this acquisition, Henry Schein will now serve dental, physician and animal health practitioners across the U.K. Henry Schein expects the acquisition to be neutral to 2007 EPS and \$.01 to \$.02 accretive to 2008 diluted EPS. Terms of the transaction were not disclosed.

"Dunlops and Henry Schein share a commitment to customer satisfaction and we are delighted to enter the U.K. animal health market in such a strong position," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "In 2006 we expanded our animal health business through the acquisition of NLS Animal Health in the U.S. and Provet in Switzerland. Today, we further expand our overall animal health business through the acquisition of Dunlops, strengthening our European animal health business, and deepening our management team. Henry Schein's animal health business now spans six European countries, including Austria, Germany, Portugal, Spain, Switzerland, and the U.K."

Dunlops' revenue was GBP 148.5 million (approximately \$300 million) for the year ended September 30, 2006. Henry Schein believes there is opportunity for improving Dunlops operating margins over the next several years.

Established in 1921, W. & J. Dunlop Ltd. is a leading supplier of animal health products and services in the U.K., covering all of England, Scotland and Wales. The Company offers customers a comprehensive product selection of approximately 14,000 items including pharmaceuticals, instruments, equipment and consumables.

### About Henry Schein

Henry Schein, a Fortune 500(R) company, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 500,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 85,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.

Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as ArubA(R), the Company's electronic catalog and ordering system. Its leading practice-management software solutions have been installed in more than 50,000 practices, including DENTRIX(R) and Easy Dental(R) for dental practices, MicroMd(R) for physician practices, and AVImark(R) for animal health clinics.

Headquartered in Melville, N.Y., Henry Schein employs nearly 12,000 people and has operations in 19 countries. The Company's net sales reached a record \$5.05 billion in 2006. For more information, visit the Henry Schein Web site at [www.henryschein.com](http://www.henryschein.com).

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors which, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: competitive factors; changes in the healthcare industry; changes in government regulations that affect us; financial risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service trouble with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

CONTACT: Henry Schein, Inc.  
Steven Paladino, 631-843-5500  
Executive Vice President and Chief Financial Officer  
[steven.paladino@henryschein.com](mailto:steven.paladino@henryschein.com)  
or  
Investors:  
Neal Goldner, 631-845-2820

Vice President, Investor Relations  
neal.goldner@henryschein.com

or

Media:

Susan Vassallo, 631-843-5562

Vice President, Corporate Communications

susan.vassallo@henryschein.com

SOURCE: Henry Schein, Inc.